# GLP-1 Dosing Errors in FDA Adverse Event Reports | This GLP Across 243,114 GLP-1 adverse event records, frequently reported terms included incorrect dose administered and extra dose administered alongside nausea and vomiting. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-dose-errors-in-adverse-reports Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # GLP-1 Dosing Errors in FDA Adverse Event Reports Among the terms reported most often for these drugs are incorrect dose, extra dose and off-label use. Those describe what somebody did, not what the drug did. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Frequently reported terms — use-process shaded · incorrect dose administered · how it was used · nausea · injection-site pain · diarrhea · vomiting · off-label use · how it was used · extra dose administered · how it was used · 243,114 records. The list is not ranked, and none of it is a rate. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 243,114 GLP-1 records where the drug was the primary suspect, from the FDA's reporting system, 2021 to 2026. - Frequently reported terms included incorrect dose administered, off-label use and extra dose administered, alongside nausea, vomiting and diarrhea. - The authors call those first three use-process issues rather than adverse drug reactions. - Tirzepatide accounted for 133,100 records, semaglutide 55,619, dulaglutide 38,406. - None of this is a rate. The authors say no source here estimates incidence, comparative risk or causality. Three of the terms turning up repeatedly in these reports are not descriptions of what the drug did to somebody. They are descriptions of what somebody did with the drug, and the authors separate the two explicitly — a distinction [a product page never makes](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## What a record is A case-product entry in the FDA’s Adverse Event Reporting System where a GLP-1 drug was named the primary suspect, after removing deleted cases, keeping only the latest version of each, and deduplicating. [\[1\]](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports#ref-1) That produced 243,114 records inside a background of 8,995,547 reports covering everything else. Somebody — a patient, a clinician, a manufacturer — decided each of those was worth submitting. There is no denominator of users anywhere in it. ## Two different kinds of thing in one list Nausea, vomiting, diarrhea and [injection-site pain](https://thisglp.com/research/where-should-you-inject-ozempic) are effects of a drug. Incorrect dose administered, extra dose administered and off-label use are events in the handling of a product. The authors put it as medication-use terms reflecting use-process rather than conventional adverse-drug-reaction issues, and they build a whole prioritized domain around medication-use and device events alongside the clinical ones — gastrointestinal intolerance, impaired gastric emptying, pancreatobiliary, renal and dehydration events, and hypoglycemia. Why that distinction matters more here than for most drugs A weekly self-injected drug with a dose that escalates on a schedule puts the administration in the hands of the person taking it, every week, for as long as they take it. Getting the dose wrong is a failure mode built into the product rather than into the molecule — and it is the failure mode a leaflet, a pharmacist or a follow-up appointment exists to prevent. Where a product arrives without those, [what happens outside a controlled setting](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) includes this. ## The counts by drug are not a comparison Tirzepatide accounted for 133,100 records, semaglutide 55,619 and dulaglutide 38,406. That ordering says nothing about which drug is riskier. Reporting volume follows how many people take something, how long it has been on the market, how much press it has had, and who is being prompted to report — which is why [a count of reports is not a count of events](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes), and why the authors say explicitly that none of their sources estimates incidence, comparative risk or causality. ## What it is actually for Deciding what to look at next. The authors describe their output as signal prioritization and medication-safety evidence, cross-checked against Canadian reports and against the FDA’s own labeling changes. Read that way it is useful and modest: a map of where to point a proper study. Read as a league table of harm it is worthless, and it will be read that way, which is the standing fate of [every spontaneous reporting analysis](https://thisglp.com/research/glp1-and-suicidal-ideation) that reaches a headline. ## Frequently asked What gets reported most often for these drugs? The published list includes incorrect dose administered, nausea, injection-site pain, diarrhea, vomiting, off-label use and extra dose administered. The abstract does not rank them. Why separate dose errors from side effects? Because they are different failures. The authors describe medication-use terms as reflecting the use process rather than conventional adverse drug reactions — what somebody did with the product, not what the product did. Does tirzepatide having more reports mean it is riskier? No. Reporting volume follows how many people take a drug, how long it has been sold and how much attention it has had. The authors state no source here estimates comparative risk. Can you get a rate out of this? No. There is no count of how many people took anything, and the authors say the findings are signal prioritization rather than incidence. ## Sources 1. \[1\] Ren L, et al. (2026). Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study Diabetes, Obesity and Metabolism. [PMID 42687799](https://pubmed.ncbi.nlm.nih.gov/42687799/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness)